PANMINERVA MEDICA is a distinguished journal published by EDIZIONI MINERVA MEDICA, focusing on the multifaceted field of medicine since its inception in 1959. With an ISSN of 0031-0808 and an E-ISSN of 1827-1898, this journal is esteemed for its rigorous peer-review process and its contribution to clinical and experimental research across various domains of medicine. Based in Italy, it holds a commendable position in the 2023 Scopus rankings, where it is placed in the 84th percentile among general medicine journals, highlighting its relevance and scholarly impact. As a Q3 category journal in the medicine (miscellaneous) quartiles, PANMINERVA MEDICA is committed to disseminating high-quality research, fostering scientific dialogue, and advancing medical knowledge globally. While currently not offering open access, it serves as a vital resource for researchers, practitioners, and students seeking to stay at the forefront of medical advancements. The journal is poised to continue its tradition of excellence as it converges into 2024, ensuring robust discourse in healthcare and clinical practices.

Neurodegenerative Diseases, published by KARGER, is a prominent academic journal dedicated to advancing the field of neurology and neuroscience. With an ISSN of 1660-2854 and E-ISSN 1660-2862, this journal serves as a vital platform for researchers, professionals, and students engaged in the exploration of neurodegenerative disorders from various perspectives, including clinical applications and therapeutic interventions. Spanning two decades since its inception in 2004 and set to converge in 2024, it has steadily built a reputation within the academic community, achieving a commendable Q2 ranking in clinical neurology and Q3 in general neurology according to the 2023 category quartiles. The journal boasts an impressive Scopus rank of 114/400 (71st percentile) in clinical neurology and 58/192 (70th percentile) in neuroscience neurology. While not classified as open access, the publication provides critical insights into the latest research and developments, making it an essential resource for anyone dedicated to understanding and combating neurodegenerative diseases.

FOLIA NEUROPATHOLOGICA is a distinguished Open Access journal specializing in the fields of Neurology and Pathology, published by the reputable TERMEDIA PUBLISHING HOUSE LTD. With an ISSN of 1641-4640 and E-ISSN 1509-572X, this journal has been a vital resource for the dissemination of high-quality research since its inception in 1994. Covering a broad spectrum of topics within neuropathology, the journal emphasizes clinical findings and forensic implications, making it an essential platform for healthcare professionals, researchers, and students alike. With impressive impact factors positioning it in the Q3 category for both Neurology (clinical) and Pathology and Forensic Medicine, FOLIA NEUROPATHOLOGICA occupies a significant place among its peers, ranked within the 36th to 46th percentiles on Scopus. Scholars can benefit from the Open Access model implemented since 2005, ensuring wide accessibility and distribution of critical research outputs aimed at advancing both clinical practices and academic knowledge. Based in Poland, at KLEEBERGA 2, POZNAN 61-615, this journal continues to shape the discourse in neuropathology and related fields.

ACTA NEUROLOGICA SCANDINAVICA is a prestigious journal published by Wiley that has significantly contributed to the field of neurology and neuroscience since its inception in 1961. With a broad scope encompassing clinical and experimental research, this journal is esteemed for its rigorous peer-review process and high-quality publications. Located in the United Kingdom, it is recognized in the 2023 category quartiles as Q1 in Medicine (miscellaneous) and Q2 in both Neurology and Clinical Neurology, indicating its strong influence and relevance within the medical community. With an H-index demonstrating consistent citation impact, ACTA NEUROLOGICA SCANDINAVICA holds a Scopus rank of #86 out of 400 in Clinical Neurology, reflecting its contribution to advancing current knowledge and practice. Researchers, professionals, and students alike will find in this journal a valuable resource for the latest findings, discussions, and developments in understanding neurological disorders and treatments, furthering educational and clinical endeavors alike.

EXPERT REVIEWS IN MOLECULAR MEDICINE, published by Cambridge University Press, stands at the forefront of research in the fields of Molecular Biology and Molecular Medicine. With an impressive impact factor reflecting its Q1 status in both relevant categories, this journal serves as an essential platform for disseminating cutting-edge reviews and critical assessments that are vital for advancing our understanding of molecular mechanisms in health and disease. Established in 1997 and continuously evolving until 2024, it features contributions from leading experts that highlight emerging trends and innovative methodologies. Researchers, professionals, and students are encouraged to engage with the content, benefiting from the journal’s rigorous peer-review process and its commitment to academic excellence, making it a valuable resource within the scientific community.

World Journal of Clinical Oncology, published by BAISHIDENG PUBLISHING GROUP INC, stands as a vital resource in the realm of oncology, providing a dedicated platform for the dissemination of cutting-edge research and clinical advancements. With an ISSN of 2218-4333, this journal facilitates a comprehensive exploration of modern oncology challenges and breakthroughs, targeting researchers, healthcare professionals, and students alike. Although it operates under the traditional subscription model, the impactful nature of its content is reflected in its notable ranking of 60 out of 334 in the category of Medicine _ Oncology, placing it in the 82nd percentile among peer publications. Covering significant topics in clinical oncology from 2014 to 2018, the journal has been instrumental in addressing evolving oncology practices and patient care innovations. By publishing high-quality studies, it remains an essential tool for advancing knowledge and fostering collaboration within the global oncology community.

Human Gene is an innovative open access journal published by ELSEVIER, dedicated to the ever-evolving field of genetics. Established in 2022, this journal serves as a vital resource for researchers, professionals, and students alike, aiming to facilitate the dissemination of groundbreaking research and advancements in both basic and clinical genetics. With an ISSN of 2773-0441, Human Gene focuses on providing a platform for high-quality studies that investigate genetic mechanisms, their implications in health and disease, and novel therapeutic strategies. The journal currently holds a Q4 ranking in both Genetics and Clinical Genetics categories, reflecting its emerging status within the scientific community, and strives to enhance its impact to better serve an engaged audience. With its base in Amsterdam, Netherlands, Human Gene is committed to making research accessible through its open access model, inviting contributions that advance our understanding of human genetics and foster collaboration across disciplines.

METABOLIC BRAIN DISEASE, published by SPRINGER/PLENUM PUBLISHERS, is a leading journal dedicated to advancing our understanding of the metabolic processes impacting brain health and disease. Established in 1986 and set to continue until 2024, this journal encompasses a wide range of interdisciplinary research that intersects the fields of Biochemistry, Cellular and Molecular Neuroscience, and Neurology, as evidenced by its notable quartile placements in Q2 and Q3 for 2023. With an ISSN of 0885-7490 and an E-ISSN of 1573-7365, it serves as a vital resource for researchers and practitioners aiming to deepen their insights into cerebral metabolic disorders and their implications. Although currently not an Open Access option, its rigorous peer-review process ensures that high-quality, impactful research reaches its audience. Showcasing a significant rank within the top percentile of its categories, METABOLIC BRAIN DISEASE is instrumental in shaping the future of neurological research and clinical applications.

GENE THERAPY, published by SpringerNature, is a prestigious academic journal at the forefront of research in the fields of genetics, molecular biology, and molecular medicine. Since its inception in 1994, this journal has evolved into a vital resource for scholars, practitioners, and students, providing cutting-edge insights into gene therapy techniques and innovations. With an impressive impact factor reflecting its significant influence— ranking in the Q1 quartile across multiple categories in 2023—GENE THERAPY offers rigorous peer-reviewed articles that address both basic and applied aspects of gene therapy. The journal is recognized for its role in promoting advancements in therapeutic strategies, thus enhancing understanding of genetic disorders and treatment efficacy. Researchers will find this journal invaluable for publishing their findings, staying updated on the latest breakthroughs, and fostering interdisciplinary collaborations. Engage with the latest in gene therapy by accessing this influential platform, and contribute to a field that holds the potential to transform healthcare outcomes worldwide.

BLOOD CELLS MOLECULES AND DISEASES is a prominent multidisciplinary journal published by Academic Press Inc., Elsevier Science, specializing in the fields of hematology, molecular biology, and cell biology. With an ISSN of 1079-9796 and an E-ISSN of 1096-0961, this journal serves as a vital resource for researchers, professionals, and students exploring the complex interplay between blood cells and their corresponding molecular pathways in disease states. Spanning topics from cellular mechanisms to therapeutic advancements, BLOOD CELLS MOLECULES AND DISEASES holds a commendable reputation with a 2023 category quartile ranking of Q2 in Hematology and Q3 in several related fields. This journal not only provides a platform for the dissemination of innovative research but also fosters collaboration and knowledge exchange within the scientific community. As it converges from 1995 to 2025, the journal continues to impact the medical and biological sciences significantly, making it an essential tool for advancing our understanding of hematologic diseases.